News related to Epivir-HBV (Lamivudine) and/or conditions it is approved for
Entecavir Achieves High Response Rate In Real-life Clinical Management Of Patients With Chronic Hepatitis B
Source: Liver Disease / Hepatitis News From Medical News Today [2009.11.04]
The nucleoside analogue entecavir (Baraclude, Bristol-Myers Squibb) achieves a high response rate and progressive decline in liver stiffness in patients with chronic hepatitis B, according to results from the first study in 'real-life' clinical practice reported at the Annual Meeting of the American Association for the Study of Liver Diseases (31 October - 3 November, 2009).
BARACLUDE(R) (entecavir) Demonstrated Greater Antiviral Efficacy Compared To Adefovir In New Study Of Chronic Hepatitis B Patients With Cirrhosis
Source: Liver Disease / Hepatitis News From Medical News Today [2009.11.03]
Bristol-Myers Squibb (NYSE: BMY) today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B patients with decompensated cirrhosis, in which BARACLUDE demonstrated greater viral suppression compared to adefovir. The new BARACLUDE data were presented today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
|
